Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2440926
Max Phase: Preclinical
Molecular Formula: C84H113F3N18O14
Molecular Weight: 1541.91
Molecule Type: Unknown
Associated Items:
ID: ALA2440926
Max Phase: Preclinical
Molecular Formula: C84H113F3N18O14
Molecular Weight: 1541.91
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NCCN(CCNC(=O)CCCCC(=O)NCCCCNC(=O)/N=C(/N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(O)cc1)CCNC(=O)CCCCC(=O)NCCCCNC(=O)/N=C(/N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(O)cc1.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C82H112N18O12.C2HF3O2/c83-45-54-100(55-52-88-71(105)35-15-13-33-69(103)86-46-17-19-48-92-81(111)98-79(84)90-50-21-31-67(75(107)94-57-59-37-41-65(101)42-38-59)96-77(109)73(61-23-5-1-6-24-61)62-25-7-2-8-26-62)56-53-89-72(106)36-16-14-34-70(104)87-47-18-20-49-93-82(112)99-80(85)91-51-22-32-68(76(108)95-58-60-39-43-66(102)44-40-60)97-78(110)74(63-27-9-3-10-28-63)64-29-11-4-12-30-64;3-2(4,5)1(6)7/h1-12,23-30,37-44,67-68,73-74,101-102H,13-22,31-36,45-58,83H2,(H,86,103)(H,87,104)(H,88,105)(H,89,106)(H,94,107)(H,95,108)(H,96,109)(H,97,110)(H4,84,90,92,98,111)(H4,85,91,93,99,112);(H,6,7)/t67-,68-;/m1./s1
Standard InChI Key: NPHSKAKDPVIVPI-UKLKETJRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1541.91 | Molecular Weight (Monoisotopic): 1540.8707 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Keller M, Kaske M, Holzammer T, Bernhardt G, Buschauer A.. (2013) Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors., 21 (21): [PMID:24074877] [10.1016/j.bmc.2013.08.065] |
Source(1):